MDT-AP-0720
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 60
- os_event
- false
- age_years
- 13.5
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.649592341
- umap2_2d
- 3.18402007
- umap1_3d
- 2.279548035
- umap2_3d
- -1.743785813
- umap3_3d
- -1.568843802
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.330
- PANCREAS_BETA_CELLS+0.330
- XENOBIOTIC_METABOLISM+0.330
- COAGULATION+0.320
- KRAS_SIGNALING_DN+0.320
- OXIDATIVE_PHOSPHORYLATION+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- ALLOGRAFT_REJECTION+0.250
- APICAL_JUNCTION+0.230
- APICAL_SURFACE+0.230
Top 10 suppressed
- G2M_CHECKPOINT-0.470
- ANDROGEN_RESPONSE-0.440
- E2F_TARGETS-0.440
- PROTEIN_SECRETION-0.390
- HEDGEHOG_SIGNALING-0.340
- MITOTIC_SPINDLE-0.340
- MTORC1_SIGNALING-0.320
- MYC_TARGETS_V1-0.290
- UV_RESPONSE_DN-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.897 |
| 2 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.881 |
| 3 | MNG718 | — | — | 0.876 |
| 4 | ERR2598280 | fetal | fetal | 0.864 |
| 5 | ca188ec2-4185-4871-b71b-d024a37e5654 | — | — | 0.862 |
| 6 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.854 |
| 7 | SRR1433600 | GTEX | — | 0.846 |
| 8 | ERR2598335 | fetal | fetal | 0.846 |
| 9 | MNG1103 | — | — | 0.841 |
| 10 | TCGA-BH-A5J0-01A-11R-A27Q-07 | — | B | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |